06826.HK
Shanghai Haohai Biological Technology Co., Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 16.73
−0.36%Year over year
Reported trailing growth
- Revenue
- -10.5%
- EBITDA
- -70.0%
- EBIT
- -42.9%
- EPS
- -57.1%
- Free cash flow
- -33.9%
- Operating cash flow
- -20.0%
Forward estimates
Based on analyst estimates
- Revenue
- -6.0%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +5.2%
- EBITDA
- -2.2%
- EBIT
- +12.5%
- Net income
- +10.7%
- EPS
- +1.3%
- Free cash flow
- +10.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026